The Eluvia drug-eluting vascular stent system has been approved by the FDA, device maker Boston Scientific announced Sept. 24—just two days after results from the IMPERIAL trial were presented at the Transcatheter Cardiovascular Therapeutics 2018 meeting.
A novel, polymer-free amphilius-eluting stent known as the “Cre8” was proven noninferior to the latest-generation permanent polymer drug-eluting stent in the first large-scale trial of its kind, according to research presented at the Cardiovascular Research Foundation’s 30th annual TCT conference in San Diego.
SAN DIEGO — An endovascular ultrasound-based renal denervation (RDN) approach led to greater reductions in blood pressure than radiofrequency ablation in patients with resistant hypertension, according to the first randomized trial to compare the techniques.
A report published by charity organization Cancer Research U.K. suggests obesity is on track to eclipse smoking as the greatest cause of preventable cancer in British women—something experts say could happen by 2043, the Guardian has reported.
OAC-ALONE, the first randomized trial to test the efficacy of oral anticoagulation (OAC) alone against combined OAC and a single antiplatelet agent (APT) in patients with atrial fibrillation and stable coronary artery disease, was unable to establish noninferiority of OACs to dual therapy, according to data presented at the 30th annual TCT conference in San Diego.
Height—and the genes that influence it—are important predictors for the development of varicose veins, according to a study out of Stanford University.
The Orsiro drug-eluting stent. Photo courtesy of Biotronik.
Resolute Onyx, a polymer-coated zotarolimus-eluting stent, has been proven safe and effective in an all-comer population of more than 2,000 heart patients, according to late-breaking results of the BIONYX trial.
SAN DIEGO — General and local anesthesia are comparably safe and effective during transcatheter aortic valve replacement (TAVR) procedures, according to the first randomized trial to compare the two approaches.
The Abbott MitraClip is the primary structural heart device used in transcatheter edge-to-edge repairs (TEER) of the mitral valve leaflets. Image courtesy of Abbott.
Compared to heart failure patients with severe secondary mitral regurgitation who were treated with guideline-directed medical therapy alone, those randomized to a MitraClip procedure plus optimal medical therapy demonstrated relative reductions of 47 percent for heart failure hospitalizations and 38 percent for mortality at two years of follow-up.
The Orsiro drug-eluting stent. Photo courtesy of Biotronik.
SAN DIEGO — The ultra-thin Orsiro drug-eluting stent (DES) maintained superior outcomes at two years of follow-up in a head-to-head trial against Abbott’s Xience stent, according to results presented this weekend at Transcatheter Cardiovascular Therapeutics 2018 and published online in the Journal of the American College of Cardiology.
![Large peridevice leaks after left atrial appendage occlusion (LAAO) are incredibly rare and not associated with a greater risk of adverse outcomes, according to new research published in JACC: Clinical Electrophysiology.[1] Smaller residual links are more common, however, and associated with a risk of thromboembolic and bleeding events.](/sites/default/files/styles/top_stories/public/2018-08/olderpatient-doctor.jpg.webp?itok=Cv18wcDr)
